DSIP (Delta Sleep-Inducing Peptide)

Naturally occurring nonapeptide that promotes delta (slow-wave) sleep without sedation. Normalizes disrupted sleep patterns, reduces stress hormones, and enhances restorative deep sleep.

Overview

Also Known As

Delta Sleep Inducing Peptide, Deltaran, DSIP

Mechanism of Action

Modulates GABAergic and glutamatergic neurotransmission. Reduces somatostatin, promotes GH release during sleep. Modulates ACTH/cortisol axis. Influences endogenous opioid system. Normalizes sleep architecture without sedation.

Product

Delta Sleep Inducing Peptide, Deltaran, DSIP vial

Dosing & Administration

Typical protocols and routes

Half-Life

Approximately 15 minutes (rapid enzymatic degradation); effects on sleep persist for hours

Administration Routes

subcutaneousintravenousintranasal

Dosing Protocols

Normal Protocol:
5 mg vial reconstituted with 2 mL bacteriostatic water (concentration: 2.5 mg/mL).
Draw 10 units (0.1 mL) on a 100-unit insulin syringe = 250 mcg per dose.
Inject subcutaneously once daily. Vial lasts 20 days.

Advanced Protocol:
5 mg vial reconstituted with 1 mL bacteriostatic water (concentration: 5 mg/mL).
Draw 10 units (0.1 mL) on a 100-unit insulin syringe = 500 mcg per dose.
Inject subcutaneously once daily. Vial lasts 10 days.

Research

Key findings and status

Key Research Findings

Schoenenberger and Monnier (1977): discovery. Schneider-Helmert (1986): improved sleep in chronic insomniacs. Stress-protective properties documented. Explored for alcohol/opioid withdrawal, pain management, and narcolepsy.

Detailed Information

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide first isolated from rabbit brain during induced sleep by Schoenenberger and Monnier in 1977. It is one of the few peptides that directly modulates sleep architecture, specifically promoting delta (slow-wave) sleep — the deepest and most restorative sleep stage critical for growth hormone release, immune function, and memory consolidation.

Mechanism of Action

DSIP mechanism is multifaceted and not fully elucidated. It modulates GABAergic and glutamatergic neurotransmission, reduces somatostatin release (indirectly promoting GH secretion during sleep), modulates corticotropin (ACTH/cortisol) secretion, and influences the endogenous opioid system. It appears to act as a sleep-promoting neuromodulator rather than a sedative, normalizing disturbed sleep patterns without causing sedation or next-day impairment.

Research Evidence

Human clinical studies by Schneider-Helmert and Schoenenberger (1986) demonstrated that DSIP administration improved sleep quality in chronic insomniacs, with particular improvement in sleep onset latency and delta sleep duration. Studies have also shown stress-protective properties, with DSIP reducing stress-induced cortisol elevation and normalizing disrupted sleep patterns in stressed individuals. Additional research has explored analgesic properties and potential in withdrawal syndromes (alcohol, opioid).

Safety & Legal

Side Effects & Warnings

Very few reported. No sedation or next-day impairment. No dependence observed. Occasional transient warmth/flushing.

Legal Status

Research use only

Molecular Data

Chemical properties

Molecular Weight

848.8 g/mol

Amino Acid Sequence

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu